| 摘要 |
The compositions and compounds of Formula I, Formula II, Formula III, Formula IV which includes topoisomerase inhibitor molecular conjugates or its polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These compounds may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration, delayed release or sustained release, transmucosal, syrup, intravenous, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, nanoparticle, buccal administration or transdermal administration. Such compositions may be used to treatment of metastasis, neoplasms, metastatic carcinoma of the colon or rectum, metastatic breast cancer, platinum-resistant ovarian cancer, bevacizumab (avastin)-refractory high-grade glioma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), GI and solid tumors. |
